Product Program year 2025 Source: CMS Open Payments

Monoferric

Drug Hematology

NDC 73594-9310-1

Open in the dashboard

General payments

$3,712,946

18,958 payments

Research payments

$0

0 payments

Through program year 2025, $3,712,946 in general payments and $0 in research payments were reported against Monoferric (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $453,938 6,095
2024 General $1,400,294 4,806
2023 General $1,095,836 4,934
2022 General $762,878 3,123

Breakdown

Who paid General payments · program years 2022–2025
  1. Pharmacosmos Therapeutics Inc. $3,712,946 18,958 payments
Top recipients General payments · program year 2025
  1. Joshua Strauss Hematology & Oncology · Springfield, NJ $46,389 10% · 48 payments
  2. Steven Fein Hematology & Oncology · Miami, FL $35,867 8% · 46 payments
  3. Hassan Kaleem Hematology & Oncology · Tulsa, OK $34,746 8% · 49 payments
  4. Christopher Chen Hematology & Oncology · Tucson, AZ $33,706 7% · 49 payments
  5. Suresh Ratnam Medical Oncology · McAllen, TX $22,088 5% · 17 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $229,494 51% · 938 practitioners
  2. Nurse Practitioner $39,811 9% · 422 practitioners
  3. Medical Oncology Internal Medicine $37,320 8% · 283 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $35,426 8% · 765 practitioners
  5. Nephrology Internal Medicine $15,924 4% · 62 practitioners

The top 5 of 102 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New Jersey $69,734 15% · 232 recipients
  2. Florida $63,809 14% · 546 recipients
  3. Oklahoma $44,218 10% · 169 recipients
  4. Arizona $39,045 9% · 135 recipients
  5. Texas $33,392 7% · 284 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to MONOFERRIC
Billing code Providers Services Paid by Medicare
Injection, ferric derisomaltose, 10 mg J1437 969 3,751,157 $59,095,345

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

18,958 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record